These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15625834)

  • 21. Detection of factor V Leiden in Thai patients with venous thrombosis.
    Prayoonwiwat W; Arnutti P; Hiyoshi M; Nathalang O; Suwanasophon C; Kokaseam R; Krutvecho T; Tatsumi N
    Asian Pac J Allergy Immunol; 2000 Jun; 18(2):105-8. PubMed ID: 10928623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
    Ivey LM; Thom JY; Ivey JG; Baker RI
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
    Jadaon MM; Dashti AA; Lewis HL
    Diagn Mol Pathol; 2010 Sep; 19(3):180-3. PubMed ID: 20736749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
    Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
    Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of the Factor V E666D Mutation and Its Correlation With Activated Protein C Resistance in the Chinese Population.
    Xin-Guang C; Yong-Qiang Z; Shu-Jie W; Lian-Kai F; Hua-Cong C
    Clin Appl Thromb Hemost; 2015 Jul; 21(5):480-3. PubMed ID: 24335247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes.
    Segers O; Simioni P; Tormene D; Bulato C; Gavasso S; Rosing J; Castoldi E
    J Thromb Haemost; 2012 Jan; 10(1):73-80. PubMed ID: 22044617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activated protein C resistance: a study among 60 thromboembolic patients in the Singapore population.
    Lim LC; Tan HH; Lee LH; Tien SL; Abdul Ghafar A
    Ann Acad Med Singap; 1999 Mar; 28(2):252-5. PubMed ID: 10497677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model.
    van der Neut Kolfschoten M; Dirven RJ; Tans G; Rosing J; Vos HL; Bertina RM
    Blood Coagul Fibrinolysis; 2002 Apr; 13(3):207-15. PubMed ID: 11943934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early days of APC resistance and FV Leiden.
    Dahlbäck B
    Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
    Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
    Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
    Schöni R; Quehenberger P; Wu JR; Wilmer M
    Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?
    Biswas A; Bajaj J; Ranjan R; Meena A; Akhter MS; Yadav BK; Sharma V; Saxena R
    Clin Chim Acta; 2008 Jun; 392(1-2):21-4. PubMed ID: 18342013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF; Lensen RP; Bertina RM
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The incidence of factor V Leiden in a normal Irish population and its relationship to the laboratory diagnosis of APC resistance.
    Vaughan J; Power C; Nolan C; McCarthy D; Shirley I
    Thromb Haemost; 1999 Apr; 81(4):661-3. PubMed ID: 10235460
    [No Abstract]   [Full Text] [Related]  

  • 36. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
    Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
    Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke.
    De Lucia D; Papa ML; Ammendola F; Pezzella S; Del Giudice V; Marotta R; Renis V; Di Mauro C; Maisto G; Masi S; Nina P; Franco A; Schisano G
    J Neurosurg Sci; 1999 Mar; 43(1):45-50; discussion 50-1. PubMed ID: 10494665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
    Paspatis GA; Sfyridaki A; Papanikolaou N; Triantafyllou K; Livadiotaki A; Kapsoritakis A; Lydataki N
    Pathophysiol Haemost Thromb; 2002; 32(1):2-7. PubMed ID: 12214157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations.
    Endrikat J; Noah M; Gerlinger C; Bannemerschult R; Junge W; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Oct; 64(4):217-22. PubMed ID: 11747870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation.
    de Ronde H; Bertina RM
    Blood Coagul Fibrinolysis; 1999 Jan; 10(1):7-17. PubMed ID: 10070830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.